An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors

This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.

Trial Details

NCT ID
NCT06942143
Phase
PHASE1
Sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Super1 TCR-T
Locations (sample)
  • Guangzhou, Gaungdong, China|23.11667,113.25

Key Eligibility Criteria

  • Sign informed consent before conducting any trial-related activities;
  • Age of 18-75 years old, male or female;
  • Patients with first-line treatment failure;
  • Measurable lesions according to RECIST1.1 criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →